Earnings results for Osmotica Pharmaceuticals (NASDAQ:OSMT)
Osmotica Pharmaceuticals plc is expected* to report earnings on 03/30/2021 after market close. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.16. The reported EPS for the same quarter last year was $0.06.
Analyst Opinion on Osmotica Pharmaceuticals (NASDAQ:OSMT)
4 Wall Street analysts have issued ratings and price targets for Osmotica Pharmaceuticals in the last 12 months. Their average twelve-month price target is $9.25, predicting that the stock has a possible upside of 131.25%. The high price target for OSMT is $11.00 and the low price target for OSMT is $8.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Osmotica Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $9.25, Osmotica Pharmaceuticals has a forecasted upside of 131.3% from its current price of $4.00. Osmotica Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Osmotica Pharmaceuticals (NASDAQ:OSMT)
Osmotica Pharmaceuticals does not currently pay a dividend. Osmotica Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Osmotica Pharmaceuticals (NASDAQ:OSMT)
In the past three months, Osmotica Pharmaceuticals insiders have not sold or bought any company stock. Only 5.30% of the stock of Osmotica Pharmaceuticals is held by insiders.
Earnings and Valuation of Osmotica Pharmaceuticals (NASDAQ:OSMT
Earnings for Osmotica Pharmaceuticals are expected to decrease in the coming year, from ($0.56) to ($0.75) per share. The P/E ratio of Osmotica Pharmaceuticals is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Osmotica Pharmaceuticals is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Osmotica Pharmaceuticals has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here